Based on the success of preclinical studies, the PATH Malaria Vaccine Initiative (MVI) and Inovio announced a follow-on collaboration to advance Inovio's malaria DNA vaccine and electroporation technology into a phase I/IIa clinical trial in 2014. Established at PATH through an initial grant from the Bill & Melinda Gates Foundation, MVI's mission is to accelerate the development of malaria vaccines and ensure their availability and accessibility in the developing world.
Corporate DevelopmentInovio continues to advance discussions with large pharmaceutical companies with the goal of securing strategic partnerships to advance the development of SynCon® vaccines.
Subsequent to the quarter, Inovio and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) received a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of Inovio's next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation.
Inovio was recognized with Vaccine Industry Excellence (ViE) Awards for "Best Therapeutic Vaccine" and "Best Early Stage Biotech" at the World Vaccine Congress. The ViE Awards recognize outstanding vaccine advancements and achievements of vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders.
About Inovio Pharmaceuticals, Inc. Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown i
|SOURCE Inovio Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved